Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Tonix Pharm Hld (TNXP)

0.9288   0.017 (1.85%) 01-21 00:54
Open: 0.931 Pre. Close: 0.9119
High: 0.955 Low: 0.882
Volume: 24,308,278 Market Cap: 246M
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) portfolio comprises small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company's lead vaccine candidate is TNX-1800, a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19. Its vaccines also comprise TNX-801, a live horsepox virus vaccine to protect against smallpox and monkeypox and serves as the vector platform; and TNX-2300, a second live replicating vaccine candidate for the prevention of COVID-19 that employs bovin parainfluenza virus as the vector. In addition, the company's lead CNS candidate is TNX-102 SL, which is in Phase 3 development for the management of fibromyalgia, as well as in Phase 2 studies for agitation in Alzheimer's disease and alcohol use disorder. Further, its products include TNX-1300, which is in Phase 2 development for the treatment of life-threatening cocaine intoxication; TNX-601 CR (tianeptine oxalate controlled-release tablets) that is in Phase 1 development for depression; and TNX-1900, an intranasal oxytocin as a non-addictive treatment for migraine and cranio-facial pain. Additionally, its preclinical pipeline includes TNX-1600, a triple reuptake inhibitor for posttraumatic stress disorder; TNX-1500, a monoclonal antibody to prevent and treat organ transplant rejection and autoimmune conditions; and TNX 1700, a recombinant modified form of Trefoil Family Factor 2 to treat gastric and pancreatic cancers. The company was founded in 2007 and is based in New York, New York.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.951 - 0.955 0.955 - 0.959
Low: 0.871 - 0.874 0.874 - 0.879
Close: 0.923 - 0.929 0.929 - 0.936

Technical analysis

as of: 2021-01-20 4:53:00 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 1.34     One year: 1.57
Support: Support1: 0.77    Support2: 0.54
Resistance: Resistance1: 1.15    Resistance2: 1.34
Pivot: 0.83
Moving Average: MA(5): 0.94     MA(20): 0.78
MA(100): 0.72     MA(250): 0.79
MACD: MACD(12,26): 0.08     Signal(9): 0.07
Stochastic oscillator: %K(14,3): 54.17     %D(3): 58.54
RSI: RSI(14): 65.76
52-week: High: 2.46  Low: 0.39  Change(%): -33.2
Average Vol(K): 3-Month: 2090511  10-Days: 5654538

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
TNXP has closed below upper band by 26.2%. Bollinger Bands are 97.6% wider than normal. The large width of the bands suggest high volatility as compared to TNXP's normal range. The bands have been in this wide range for 7 bars. This is a sign that the current trend might continue.

Headline News

Tue, 19 Jan 2021
You Need to See this stock? Tonix Pharmaceuticals Holding Corp. (TNXP) - Armenian Reporter

Sun, 17 Jan 2021
Hot Stock on Spotlight: Tonix Pharmaceuticals Holding Corp. (TNXP) - Armenian Reporter

Thu, 07 Jan 2021
Further Research into Psilocybin Opens New Doors for Treatment - PR Newswire UK

Tue, 05 Jan 2021
Tonix Pharmaceuticals and Massachusetts General Hospital (MGH) Enter into Research Collaboration on Tonix’s Third Generation anti-CD40-Ligand Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Kidney Transplant Rejection - Yahoo Finance

Thu, 24 Dec 2020
BUZZ-U.S. STOCKS ON THE MOVE-Alibaba, Altimmune, Tonix - Nasdaq

Wed, 11 Nov 2020
Tonix Pharmaceuticals to Participate in Upcoming November Conferences - GlobeNewswire

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency n/a
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 192
Shares Float (M) 156
% Held by Insiders 0.05
% Held by Institutions 5.25
Shares Short (K) 573
Shares Short P. Month (K) 791

Stock Financials

EPS -0.850
EPS Est This Year -3.020
EPS Est Next Year -2.470
Book Value (p.s.) 0.450
Profit Margin
Operating Margin
Return on Assets (ttm) -66.1
Return on Equity (ttm) -116.4
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -0.220
Qtrly Earnings Growth
Operating Cash Flow (M) -41
Levered Free Cash Flow (M) -31

Stock Valuations

PE Ratio -1.09
PEG Ratio
Price to Book value 2.06
Price to Sales
Price to Cash Flow -4.31

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.